icensing agreement with Emma Lewisham
Blis Technologies Limited: Ground Floor, 442 Moray Place, Dunedin Central 9016, PO Box 2208, Dunedin 9044, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
3 October 2023
Licensing agreement with Emma Lewisham
On 16 August 2023 Blis Technologies (NZX: BLT) announced a licensing agreement with a significant
Australasian cosme�c skincare company to license our cosme�c facial live probio�c serum
formula�on containing BLIS Q24®.
The agreement is with Emma Lewisham, a fast-growing cosme�c skincare company known for its
“science-led natural skincare that is cer�fied climate posi�ve.”
The agreement allows for an exclusive license to use the cosme�c live probio�c formula�on under
the Emma Lewisham brand in New Zealand, Australia and the United Kingdom, markets where Emma
Lewisham has developed a strong retail and online presence.
Emma Lewisham’s product offer “Supernatural Blemish Serum with live probio�c” will be launched
within retail and online from 3 October 2023.
Blis CEO Brian Watson said “We are thrilled to see the launch of our first Business to Business
partnership for our skincare technology. The Emma Lewisham brand is well regarded interna�onally
and we look forward to suppor�ng their growth plans with this unique product offer.”
Ends
About the BLIS Q24™ Live Probiotic Serum Technology
Enriched with a live probiotic in a shelf-stable topical format, the BLIS Q24™ Live Probiotic Serum has been shown
to address various skin concerns and help to maintain a healthier, more radiant complexion.
BLIS Q24™ is a patented strain of Micrococcus luteus, a commensal and beneficial species of bacterium
naturally found on the skin. The strain was isolated in 2004 by Professor Emeritus John Tagg, who
recognised its ability to inhibit the growth of key skin pathogens associated with skin diseases.
Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- BIF — Booster Innovation Fund: BIF – Quarterly Client Update2023-10-11
“Portfolio Highlights Portfolio company, BioLumic, has successfully partnered with seed and seedling producers based in the United States that are growing plant types including Corn, Soybean, and Cannabis. Their revolutionary UV technology delivers ultraviolet light to seeds a…”
- PEB — Pacific Edge Limited: Quarterly Update – Q2 24 Cxbladder Test Volumes Resilient2023-10-10
“11 October 2023 CXBLADDER TEST VOLUMES RESILIENT IN THE FACE OF HEADWINDS DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) announces test volumes processed at its laboratories in the second quarter of the 2024 financial year (Q2 24) fell 12% to…”
- PEB — Pacific Edge Limited: Correction of LCD Reference Number2023-07-07
“6 July 2023 PACIFIC EDGE WELCOMES STAY OF NOVITAS LCD DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today welcomes a decision from Novitas 1 and First Coast to delay the implementation of the Local Coverage Determination (LCD, L393…”